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AbstrACt
Objective To explore the impact of medication-related 
osteonecrosis of the jaw (MRONJ) on quality of life and to 
explore the attitudes and perceptions of patients towards 
the multidisciplinary approach to the prevention of the 
condition.
Design Interpretivist methodology using qualitative 
semistructured interviews.
setting Primary care general medical practices and 
secondary care dental services in England.
Participants 23 patients; 6 with MRONJ, 13 prescribed 
bisphosphonates, 4 with osteoporosis not currently 
prescribed any medication.
results Patients felt that MRONJ had a significant 
negative impact on their quality of life and had poor 
knowledge of the preventive strategies recommended 
in the literature. Patients demonstrated positive 
attitudes towards a multidisciplinary approach to care; 
however, they perceived prescribers as having the key 
role in articulating risk. Four salient and inter-related 
themes emerged from the interviews: (1) perception 
of knowledge, indicating limited awareness of the 
condition, risk factors and preventive strategies; (2) 
quality of life, indicating the lived experiences of patients 
and the physical, psychological and social impacts of 
MRONJ; (3) interprofessional management, indicating a 
perceived organisational hierarchy, professional roles and 
responsibilities, prioritising aspects of care, articulation of 
risk and communication and (4) wider context, indicating 
demands on National Health Service resources and 
barriers to dental care.
Conclusions MRONJ has a significant detrimental impact 
on quality of life, yet appropriate preventative education is 
not apparent. Effective interprofessional patient education 
and prevention to mitigate against the risk of developing 
MRONJ is required.
IntrODuCtIOn 
Medication-related osteonecrosis of the jaw 
(MRONJ) is defined as exposed bone, or 
bone that can be probed through an intra-
oral or extraoral fistula, in the maxillofa-
cial region that has persisted for more than 
8 weeks in patients with a history of treat-
ment with antiresorptive or antiangiogenic 
drugs, and where there has been no history 
of radiation therapy to the jaw or no obvious 
metastatic disease to the jaws.1 The risks for 
MRONJ are hypothesised to be related to the 
unique nature of the blood supply, and the 
anatomical structure and function of the jaw 
bones.2–6 
A number of drugs that are indicated for 
use in osteoporosis, Paget’s disease or the 
treatment of cancer have been associated with 
MRONJ. These include both oral and intrave-
nous bisphosphonates such as alendronic acid 
or zoledronate, receptor activator of nuclear 
factor kappa-beta ligand inhibitors such as 
denosumab, and antiangiogenic drugs such 
as bevacizumab, sunitinib and aflibercept.7 
In practice, the most commonly prescribed 
strengths and limitations of this study
 ► Although medication-related osteonecrosis of the 
jaw (MRONJ) is not a common finding, affected 
patients experience significant morbidity, and man-
agement of this condition warrants further study to 
improve patient care.
 ► There is limited research into the impact of MRONJ 
on patients; this is the first qualitative study that has 
explored the perceptions and consequent attitudes 
of patients and the resultant impact of the condition 
on quality of life.
 ► A qualitative method yielded rich data through in-
depth semistructured interviews with three groups 
of patients (patients with a diagnosis of MRONJ, 
patients prescribed bisphosphonates and patients 
with a diagnosis of osteoporosis who are not cur-
rently prescribed medication). Constant comparison 
with concurrent data collection and analysis allowed 
further exploration and refining of emergent themes.
 ► The study was based around an a priori assumption 
of limited knowledge among patients in relation to 
MRONJ; patients were provided a patient informa-
tion leaflet in advance, therefore exposing partici-
pants to the concepts before the interview.
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agents are oral bisphosphonates for the management of 
osteoporosis.
The major risk factor for the development of MRONJ 
is a dental extraction in a patient exposed to implicated 
medicines8; however duration of therapy with antiresorp-
tive drugs exceeding 4 years and concomitant admin-
istration of corticosteroids are also associated with an 
increased risk.1 Exact incidence and prevalence rates of 
MRONJ are unclear, with varying reports in the litera-
ture.4–6 The estimated incidence of MRONJ in patients 
with cancer treated with antiresorptive or antiangiogenic 
drugs is 1% and in patients with osteoporosis treated with 
antiresorptive drugs is 0.01%–0.1%.7
A systematic review of the diagnosis and management 
of osteonecrosis of the jaw identified the elimination or 
stabilisation of oral disease before initiating antiresorp-
tive agents as a preventative strategy for MRONJ.9 Several 
prospective studies have identified that dental screening 
and preventive strategies reduce the risk of osteonecrosis 
of the jaw.10 11 Before commencement of drugs associated 
with MRONJ, or as soon as possible thereafter, patients 
should be supported in becoming as dentally healthy as 
possible. This aim is to prioritise care that will reduce 
mucosal trauma and/or act prophylactically to help avoid 
subsequent dental extractions or conditions, which may 
further predispose the patient to surgical or dental proce-
dures that further impact on the osseous structures of the 
jaw.7
Clinical guidelines published by the Scottish Dental 
Clinical Effectiveness Programme recommend that 
patients with high-risk oncology should undergo a thor-
ough dental assessment, with necessary dental treat-
ment prior to the initiation of drug therapy.7 Guidance 
for prescribers and pharmacists also recommends that 
patients (and/or their carers) are advised that there is 
a risk of MRONJ, but should ensure that they under-
stand that the risk is small. Patients should be advised to 
make an appointment with their dentist to ensure they 
are dentally fit and inform their dentist that they will be 
taking the prescribed medication.7
A multidisciplinary approach to the prevention of 
MRONJ is recommended in the literature, incorporating 
both patient and health professional education on the 
risk of the development of MRONJ, appropriate preven-
tive measures and oral health instruction.7 12–16 Our 
recent qualitative study of general medical practitioners 
(GMPs) and pharmacists in North East England found 
that both professional groups had limited knowledge and 
awareness of MRONJ and due to the complex medical 
histories of patients, practitioners often overlooked the 
advice related to the risk and prevention of MRONJ.17
The aim of this study was to explore the impact of 
osteonecrosis of the jaw on patients, and to explore the 
attitudes and perceptions of these patients towards the 
multidisciplinary approach to the prevention of MRONJ. 
While several drugs are thought to contribute to the aeti-
ology of MRONJ, this study focused specifically on the 
association between bisphosphonates and osteonecrosis 
of the jaw and the multidisciplinary approach to the 
prevention of this rare, yet serious, adverse effect.
Aims
1. To explore the perceived impact of MRONJ on pa-
tients with a diagnosis of the condition.
2. To explore the attitudes and perceptions of patients 
towards the roles of the pharmacist, GMP and dentist 
in the prevention of MRONJ.
3. To explore the barriers and enablers to optimise risk 
prevention of MRONJ.
MethODs
Design
A grounded theory approach was used throughout this 
research.18 Constant comparison was utilised as a means 
of enriching the data through iterative data collection 
and analysis; the emergence of themes during the process 
provided the opportunity for further exploration during 
subsequent data collection.19
An initial topic guide (online supplementary document 
1) was developed by the principal investigator based on the 
published literature and the findings of our previous quali-
tative study.17 The topic guide was reviewed and refined by 
the multidisciplinary research team and served as a bench-
mark for semistructured one-to-one interviews carried 
out at the participant’s home, general medical practice or 
dental clinic. The interviews were audio-recorded and tran-
scribed verbatim to aid qualitative analysis.
Participants
Participants were recruited with the assistance of three 
National Institute for Health Research Clinical Research 
Networks (NIHR CRNs); North East and North Cumbria, 
Yorkshire and Humber, and North Thames. Three distinct 
groups were recruited to the study: (1) patients prescribed 
bisphosphonates, (2) patients with a diagnosis of osteo-
porosis not currently undergoing drug treatment and (3) 
patients with a diagnosis of MRONJ. An invitation letter 
(online supplementary documents 2–4) and participant 
information sheet (online supplementary documents 5–7) 
were posted to patients in groups 1 and 2 by their GMP and 
a convenience sample of participants who responded to the 
invitation was implemented. Participants were assigned a 
participant number to ensure anonymity.
Patients in group 3 (diagnosis of MRONJ) were 
recruited through the Oral and Dental Specialty Group 
of the NIHR CRNs; two secondary care dental hospitals 
recruited participants by posting invitation letters and 
participant information sheets to eligible patients.
Analysis
Constant comparison allowed for enrichment of data 
and for new concepts to be explored through subsequent 
interviews; Ritchie and Spencer’s framework analysis 
(2002)20 allowed salient themes to be identified from the 
data. Framework analysis involved a five-stage process: 
familiarisation with the data; development of a thematic 
 o
n
 3 M
arch 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-024376 on 3 March 2019. Downloaded from 
3Sturrock A, et al. BMJ Open 2019;9:e024376. doi:10.1136/bmjopen-2018-024376
Open access
framework; indexing data; charting of the data and 
mapping of the data. Themes were reviewed until defini-
tive concepts could be produced from the data.
Patient involvement
The principal investigator met with a patient represen-
tative from the University of Sunderland  Patient, Carer 
and Public Involvement Group to discuss the design and 
ethical implications of the study. This included the co-con-
structed design of the patient information sheet, ensuring 
informed consent and finally information regarding the 
opportunity to access further advice or support following 
their participation in the study.
results
In all, 23 patients were recruited to this study (table 1). 
In-depth semistructured interviews were carried out 
between May 2017 and March 2018 until no new themes 
emerged and current ones were exhausted. Interviews 
took place in patient’s homes, at their general medical 
practice or at their secondary care dental clinic; 1 hour 
was designated for each interview.
Perceptions of knowledge
The concept of MRONJ was introduced in the participant 
information sheet and opened up for further discussion 
during the interview; participants without a diagnosis of 
MRONJ had minimal awareness of the associated risk.
They didn’t explain about- anything about any side-ef-
fects or anything about trouble with your teeth. (B-6)
Those patients with a diagnosis of MRONJ were aware of 
the condition and how this was related to their prescribed 
medication. All patients with MRONJ stated that they 
were unaware of this risk prior to commencing treatment 
with the bisphosphonate.
Table 1 Participant characteristics
Participant Identifier Diagnosis Age range (years) Gender
1 MRONJ-1 Osteonecrosis due to bisphosphonate 50–59 Female
2 MRONJ-2 Osteonecrosis due to bisphosphonate 60–69 Male
3 MRONJ-3 Osteonecrosis due to bisphosphonate 50–59 Female
4 MRONJ-4 Osteonecrosis due to bisphosphonate 70–79 Female
5 MRONJ-5 Osteonecrosis due to bisphosphonate 60–69 Female
6 MRONJ-6 Osteonecrosis due to bisphosphonate 70–79 Female
7 B-1 Osteoporosis – prescribed bisphosphonate 60–69 Female
8 B-2 Osteoporosis –  prescribed bisphosphonate 60–69 Male
9 B-3 Osteoporosis –  prescribed bisphosphonate 60–69 Male
10 B-4 Osteoporosis –  prescribed bisphosphonate 60–69 Female
11 B-5 Osteoporosis –  prescribed bisphosphonate 60–69 Female
12 B-6 Osteoporosis –  prescribed bisphosphonate 60–69 Female
13 B-7 Osteoporosis –  prescribed bisphosphonate 60–69 Female
14 B-8 Osteoporosis –  prescribed bisphosphonate 60–69 Male
15 B-9 Osteoporosis –  prescribed bisphosphonate 50–59 Female
16 B-10 Osteoporosis –  prescribed bisphosphonate 60–69 Female
17 B-11 Osteoporosis –  prescribed bisphosphonate 70–79 Female
18 B-12 Osteoporosis –  prescribed bisphosphonate 70–79 Female
19 B-13 Osteoporosis –  prescribed bisphosphonate 70–79 Female
20 O-1 Osteoporosis –  not prescribed 
bisphosphonate
60–69 Female
21 O-2 Osteoporosis –  not prescribed 
bisphosphonate
70–79 Female
22 O-3 Osteoporosis –  not prescribed 
bisphosphonate
70–79 Female
23 O-4 Osteoporosis –  not prescribed 
bisphosphonate
80–89 Female
Four salient inter-related themes emerged from the data: (1) perceptions of knowledge; (2) quality of life; (3) interprofessional management 
and (4) wider context.
MRONJ, medication-related osteonecrosis of the jaw.
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I was given no information about that…Doctors don’t 
tell you about the side-effects of drugs. (MRONJ-6)
Most patients reported that information relating to the 
risk and preventive strategies for MRONJ complications 
had not been discussed with the prescriber or pharmacist 
on initiation. Where patients had awareness of these issues, 
the information was typically gained from the patient infor-
mation leaflet supplied with their medication.
Well, I usually read the little leaflet for any, you know, 
side-effects that they might have. (B-8)
It was clear from the discussions that the patients 
prescribed a bisphosphonate were uncertain about 
required duration of therapy; many patients had been 
prescribed the drugs for a number of years but were 
unclear on whether therapy should be continued indef-
initely or for a set period of time.
I reckon I’ve been taking it more than five years now. 
And it should- I’ve got a feeling it should’ve been re-
viewed after five years. (B-8)
Patients felt that although the internet can provide 
access to information, due to age, many people in this 
patient group have limited knowledge of, or access to, 
web-based information.
You know, it’s only since the internet that people 
able to look up on the actual – I mean, I- I’m not – I 
do use the internet, but not often or very well- I’m 
not on it every day cos I don’t have it where I live. 
(MRONJ-6)
Quality of life
Most of the patients interviewed had a complex medical 
history. The age of participants and the presence of 
comorbidities meant that osteoporosis was typically one 
of a number of ongoing medical conditions for which 
they were undergoing treatment; as a result, most patients 
were prescribed a number of medications.
At one time, when I first came to hospital, I was on 
twenty- about twenty tablets a day, you know, which is 
too much. (B-2)
Participants with a diagnosis of MRONJ highlighted the 
impact that the condition has had on their quality of life. 
Participants described experiencing a significant amount 
of pain with the condition, requiring the frequent use of 
analgesic medication.
The big problem is all my lips are tender. When I 
touch them, it - it’s just as though – I’ve never been 
hit in face, but- but I can imagine somebody hitting 
you in the face. I can imagine it feeling like that. And 
- and the tenderness, it never goes. It’s always there. 
I touch it and I feel as though I don’t want to touch 
it. (MRONJ-2)
Participants identified challenges in relation to eating 
and drinking, and the associated social anxiety of eating 
awkwardly in public.
Psychological and mental, yeah. If you’re going out 
to a restaurant, then you have to be very careful. You 
don’t want people to see that you are eating awkward-
ly. (MRONJ-5)
The psychological implications of a diagnosis of MRONJ 
were highlighted by participants; these were seen to take 
less of a priority for healthcare professionals but have a 
significant impact on the quality of patients’ lives.
This is difficult, but mentally, it gives you some kind 
of anxiety because you- you- you know your bone is 
there - a little piece of bone on your left-hand side is 
there. (MRONJ 5)
All participants with a diagnosis of MRONJ were 
required to attend secondary care dental hospitals, where 
their condition was managed and regularly reviewed. In 
some cases, patients had to travel a considerable distance 
for treatment and were required to attend frequent 
appointments in secondary care.
I mean, I go every month at the moment, it’s quite 
an- a big impact, I guess, in terms of appointments. 
Well, they- they have a look, see if it’s got any worse, 
and then record it. They often have to send me for 
more x-rays. (MRONJ-2)
Participants with a diagnosis of MRONJ expressed 
concerns regarding the potential complications of the 
disease, the need for antibiotic treatment and for surgical 
intervention.
I have had to have lots of antibiotics, it seems to keep 
getting infected. Hopefully they will keep working, 
but one time, they had to give me some extra strong 
antibiotics because the normal antibiotics didn’t 
work. (MRONJ-2)
You think, maybe perhaps in the future, you need to 
have an operation. It’s a big operation. (MRONJ-5).
Interprofessional management
It became clear from the interviews that participants 
perceived there to be a clear organisational hierarchy in 
terms of the management of their condition. Participants 
felt that it was the responsibility of the prescribing clini-
cian to provide information relating to the adverse effects 
of medication.
I think – and you needed that information, I think 
it should be the doctors telling you when- when he 
prescribes it, to say to - as a precaution, you should go 
to your dentist. (O-3)
Most participants placed trust in the professionals 
managing their care and perceived that prescribers would 
have already utilised professional judgement in relation 
to the possible risks and benefits of medication.
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I’m sure the doctor will use his own discretion, you 
know. That it is safe and appropriate. (B-2)
However, many participants identified that the risks 
and benefits of medication are not well articulated to 
patients, making it difficult to make informed decisions 
around their care.
I think they should be able to provide the risks and 
the benefit and discuss with the patient what’s prob-
ably be-best with them. I don’t think this is done very 
well. (MRONJ-6)
Due to the complexity of patient’s medical profiles and 
the associated polypharmacy, it was identified that infor-
mation is typically prioritised and that healthcare profes-
sionals only have limited time to provide information.
They haven’t got the time to go through everything 
with you. [chuckles] I think they have to pick out the 
key things. (B-1)
Participants perceived pharmacists to have an important 
role in the reinforcement of advice given by prescribers 
and were receptive to receiving information from phar-
macists relating to the administration and potential 
adverse effects of medication.
Quite often, you know, you talk to your GP and you 
go away and you just forget- you forget something 
that they’ve said. So, having it reinforced a couple of 
times I think’s a good idea. (B-8)
Pharmacists were seen as having specialised knowledge 
in relation to the adverse effects of medicines; a number 
of patients had experienced a formal medication review 
by their pharmacist and appreciated the opportunity to 
discuss their medication and adverse effects.
I feel as though the pharmacist that I go to, I could 
ask her anything and she would tell us. I have had a 
review with her, she’s very, very helpful and knowl-
edgeable about medication. (B-5)
Participants reported that dental practitioners routinely 
ask about changes to prescribed medicines during 
check-up and treatment appointments. Some partici-
pants identified that their dentist specifically asks about 
their prescribed bisphosphonate, but the interest in these 
drugs had not been explained to the participants.
You’ve got to fill a- a form in every time with your 
medicines on. And funnily enough, alendronic acid 
is the one that I often forget and miss off. And they 
have asked us ‘are you still taking that?’ (B-1)
Participants discussed the need for good communi-
cation between the professional groups to support the 
prevention of MRONJ. Participants were all happy for 
information to be shared between the professions and 
expected information regarding their treatment to be 
communicated effectively.
If the doctor has recommended me to go, I would 
think there should be at least some liaison with the 
dentist and the doctors and that was on your medical 
records to say you’re getting that check done. (O-3)
Participants also described the importance of taking 
responsibility for their own actions. If provided with infor-
mation or management advice, they perceived they ought 
to have ensured that this was acted on. Participants did 
stress that in order to take personal responsibility, they 
needed to be appropriately informed by the healthcare 
professional(s).
It’s your own responsibility. If you’ve been told about 
something properly, you know, it’s then your respon-
sibility too. You’ve got to look after yourself, you 
know. (B-2)
Wider context
Participants identified that there is an increasing 
demand on National Health Service (NHS) resources 
and perceived that all healthcare professionals have a 
heavy workload. As such, they felt that the implementa-
tion of preventive strategies could potentially place more 
demands on staff time and the already limited appoint-
ment schedules.
Doctors are so over-stretched and – and – you only 
have a short time for the appointment to get the in-
formation. Sometimes you still wait forever to even 
get an appointment. (MRONJ-6)
Although most of the participants had a history of 
regular dental appointments, there was a strong feeling 
that many patients have a general reluctance to seek 
dental advice. Potential barriers such as a phobia of 
dental treatment, a perceived lack of awareness of oral 
health and the financial implications of dental treatment 
were all identified by participants.
Terrified. Uh-huh. Always have been. (B-5)
You have to pay for the examination and then obvi-
ously, depending on the amount of work that you 
need, that can be quite expensive. And not everybody 
has that money. (B-6)
DIsCussIOn
MRONJ is a serious condition that requires complex 
management, and current literature is indicative of the 
importance of preventive care interventions, due to 
the subsequent associated morbidity and challenges in 
treating osteonecrosis of the jaw.1 In this study, it was 
apparent that MRONJ has a significant effect on the 
quality of life experienced by patients who were inter-
viewed. Previously, a study of 34 patients with MRONJ 
utilising the Oral Health Impact Profile questionnaire-14 
found that the condition significantly affects the quality 
of life.21 While this provides tangible metrics regarding 
the significance of the condition of patients, it provides 
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no specific information on what this means to people in 
their daily lives. The qualitative insight generated by our 
study has provided the first documented experiences of 
this particular patient group, highlighting the significant 
issues they face and the ongoing physical, psychological 
and social distress they associate with the condition.
As MRONJ can, in many cases, be prevented with 
appropriate oral health education and preventive care, 
the importance of such measures should be stressed to all 
healthcare professionals managing this particular patient 
group. It also leads us to consider how other allied health 
professionals may also incorporate the importance of 
this into their practice with patients and their carers and 
families. Masson22 et al identified that only 11.8% of GMPs 
and 9.7% of pharmacists advised patients to inform their 
dentist they were using a bisphosphonate.22 Our previous 
qualitative study of GMPs and pharmacists in England 
also identified limited knowledge among these profes-
sional groups in relation to the risk and prevention of 
MRONJ.17
Patients from all three groups were generally unaware 
of the risks and preventive strategies, and the patients 
with MRONJ reported limited knowledge prior to diag-
nosis. A quantitative study (n=55) found that the majority 
of patients acquired knowledge about the drug they were 
prescribed from patient information leaflets (62%), with 
few patients (13%) receiving this information from their 
GMP. When asked to identify side effects of bisphospho-
nate therapy, only 32% of patients receiving IV, and 17% 
patients receiving oral, bisphosphonates were aware of 
the risk of developing osteonecrosis of the jaw.23 When 
patients in our study possessed some knowledge, this 
typically came from the information leaflet supplied with 
medication or from the internet.
Although published clinical guidelines recommend 
that patients should be referred for dental assessment 
and treatment prior to initiation of bisphosphonate 
therapy,7 it is apparent this is not happening in practice. 
A lack of knowledge in relation to the risk and appro-
priate preventative strategies by prescribers is potentially 
exposing patients to a condition with significant quality 
of life implications and represents a key medication safety 
issue. An awareness of MRONJ among prescribers is a key 
to ensuring that an appropriate risk assessment can be 
made relative to the prescribing of implicated medicines 
and the need for the effective education of patients on 
preventative strategies.
Patients prescribed bisphosphonates were confused 
about the intended duration of treatment with the drug; 
some patients were aware that the medication would 
only be prescribed for a set duration of time, whereas for 
others, this medication had already been prescribed for 
many years without any evident review.
Participants described a perceived organisational hier-
archy in relation to the management of their health; they 
expected prescribers to use professional judgement on 
the suitability of the medication for them and to provide 
information related to the adverse effects of medications. 
Many of the participants interviewed have complex medi-
cation histories, live with comorbid conditions and as a 
consequence are simultaneously prescribed multiple 
medications. Participants therefore described the need 
for prescribers to prioritise information related to their 
clinical management and in-patient education in relation 
to their polypharmacy.
Participants perceived that the pharmacist has an 
important role in reinforcing advice and were positive 
in their regard of the pharmacist’s role in providing 
information on medications and conducting medication 
reviews. Participants reported that their general dental 
practitioners were active in recording medication details 
and were also receptive to information being shared 
between medical and dental services. Key barriers in rela-
tion to the multidisciplinary prevention of MRONJ, such 
as heavy demands on NHS resources, attitudes towards 
oral health, a reluctance to attend dental appointments 
and the financial issues associated with dental care, were 
all identified by participants.
This study has explored the attitudes and perception of 
patients prescribed bisphosphonates, focusing on those 
with a diagnosis of osteoporosis. The literature is clear 
that the incidence of osteonecrosis is greater in patients 
prescribed intravenous bisphosphonates for the treat-
ment of cancer; further work exploring the management 
of this patient group and any variation in the attitudes 
towards risk and ongoing management would substan-
tially add to this body of literature.
Patients have already demonstrated positive inten-
tions to change oral health behaviours following phar-
macy-based oral health interventions24; further work to 
explore the role of the pharmacist in the interprofessional 
prevention of MRONJ should be considered. Patients in 
our study described the benefit of formal medication 
reviews with their pharmacist and a willingness to engage 
with pharmacy services to receive information related to 
the adverse effects of medication. Both the Medication 
Use Review (MUR) and New Medicine Services (NMS) 
are advanced services within the NHS Community Phar-
macy Contractual Framework in England. An MUR is a 
structured, adherence-centred polypharmacy review of 
patients prescribed multiple medicines and the NMS 
service provides support for patients with long-term condi-
tions that have been newly prescribed a medicine.25 26 
However, the MUR and NMS service specifications do not 
currently include bisphosphonates; the inclusion of this 
group of drugs could provide an opportunity for rein-
forcement of preventative advice during the initiation 
stages of treatment with bisphosphonates.
The perspective of dental practitioners on how the 
multidisciplinary team can collaborate to improve patient 
care would be important to consider before implementing 
any preventative strategies. A recent publication in British 
Dental Journal emphasised the potential benefits of inter-
professional working between pharmacy and dental 
professionals27; further work to develop such services 
could be of particular benefit to this patient group.
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COnClusIOn
MRONJ has a significant detrimental impact on patient 
quality of life, with significant physical, psychological 
and social implications. However, patients demonstrated 
limited knowledge of these risks and of the preventive 
strategies recommended for their avoidance, in the 
literature.
Patients perceive prescribers to be responsible for 
educating them on the risks associated with medica-
tions. The formal role of the pharmacist, however, can 
provide a significant opportunity to reinforce informa-
tion and provide advice to patients regarding both newly 
prescribed medications and the evaluation of their other 
pre-existing pharmacological regimes, via formal medica-
tion reviews.
Increased focus on preventative dental care with the 
education of other healthcare professionals and patients 
on the importance of oral health and preventative strate-
gies could potentially improve patient safety and prophy-
lactically reduce the risk of the development of MRONJ 
in practice.
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